Cargando…

Atypical HUS relapse triggered by COVID-19

Detalles Bibliográficos
Autores principales:	Ville, Simon, Le Bot, Sabine, Chapelet-Debout, Agnès, Blancho, Gilles, Fremeaux-Bacchi, Véronique, Deltombe, Clément, Fakhouri, Fadi
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	International Society of Nephrology. Published by Elsevier Inc. 2021
Materias:	Letter to the Editor
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7657017/ https://www.ncbi.nlm.nih.gov/pubmed/33188793 http://dx.doi.org/10.1016/j.kint.2020.10.030

Ejemplares similares

Minimal change disease relapse following SARS-CoV-2 mRNA vaccine
por: Kervella, Delphine, et al.
Publicado: (2021)

COVID-19 as a potential trigger of complement-mediated atypical HUS
por: El Sissy, Carine, et al.
Publicado: (2021)

Pregnancy-triggered atypical hemolytic uremic syndrome (aHUS): a Global aHUS Registry analysis
por: Fakhouri, Fadi, et al.
Publicado: (2021)

Eosinophilia Due to Central Venous Catheter in Hemodialysis Patients
por: Chapelet-Debout, Agnès, et al.
Publicado: (2021)

Collapsing glomerulopathy in a patient with APOL1 intermediate-risk genotype triggered by lupus nephritis and SARS-CoV-2 infection: lessons for the clinical nephrologist
por: Masset, Christophe, et al.
Publicado: (2021)

The Rational Use of Complement Inhibitors in Kidney Diseases
por: Fakhouri, Fadi, et al.
Publicado: (2022)

Treatment of atypical uraemic syndrome in the era of eculizumab
por: Fremeaux-Bacchi, Veronique
Publicado: (2012)

Atypical HUS Triggered by COVID-19: A Case Report
por: Tiwari, Vaibhav, et al.
Publicado: (2022)

Atypical hemolytic uremic syndrome
por: Loirat, Chantal, et al.
Publicado: (2011)

The global aHUS registry: methodology and initial patient characteristics
por: Licht, Christoph, et al.
Publicado: (2015)

Genetics and complement in atypical HUS
por: Kavanagh, David, et al.
Publicado: (2010)

Clinical Relapses of Atypical HUS on Eculizumab: Clinical Gap for Monitoring and Individualised Therapy
por: Teoh, Chia Wei, et al.
Publicado: (2018)

Complement and the atypical hemolytic uremic syndrome in children
por: Loirat, Chantal, et al.
Publicado: (2008)

Common genetic variants in complement genes other than CFH, CD46 and the CFHRs are not associated with aHUS
por: Ermini, Luca, et al.
Publicado: (2012)

Impact of hypertensive emergency and rare complement variants on the presentation and outcome of atypical hemolytic uremic syndrome
por: El Karoui, Khalil, et al.
Publicado: (2019)

Complement therapy in atypical haemolytic uraemic syndrome (aHUS)
por: Wong, Edwin K.S., et al.
Publicado: (2013)

Atypical HUS Associated with CFH/CFHR-1 Hybrid Gene
por: Negi, Sharon, et al.
Publicado: (2020)

Atypical HUS with multiple complement system mutations triggered by synthetic psychoactive drug abuse: a case report
por: Jelicic, Ivo, et al.
Publicado: (2023)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Post-partum atypical haemolytic-uraemic syndrome treated with eculizumab: terminal complement activity assessment in clinical practice
por: Delmas, Yahsou, et al.
Publicado: (2013)

Use of Eculizumab During Pregnancy in Kidney Transplant Recipients With Atypical HUS
por: Cheung, Chee Kay, et al.
Publicado: (2019)

Pulmonary Renal Syndrome due to Atypical HUS in a Young Gentleman
por: Rajarajan, Arun P., et al.
Publicado: (2023)

A case of adult atypical haemolytic uraemic syndrome related to anti-factor H autoantibodies successfully treated by plasma exchange, corticosteroids and rituximab
por: Lionet, Arnaud, et al.
Publicado: (2009)

A systematic review of eculizumab for atypical haemolytic uraemic syndrome (aHUS)
por: Rathbone, John, et al.
Publicado: (2013)

Atypical Hemolytic Uremic Syndrome: Differential Diagnosis from TTP/HUS and Management
por: Yenerel, Mustafa N.
Publicado: (2014)

Atypical Hemolytic Uremic Syndrome Recurrence after Renal Transplantation: C3-Glomerulonephritis as an Initial Presentation
por: Bouatou, Yassine, et al.
Publicado: (2015)

Prognostic utility of ADAMTS13 activity for the atypical hemolytic uremic syndrome (aHUS) and comparison of complement serology between aHUS and thrombotic thrombocytopenic purpura
por: Oh, Jisu, et al.
Publicado: (2019)

Atypical HUS caused by anti-complement factor H antibody: a hematologist's perspective
por: Kumar, Meet, et al.
Publicado: (2015)

Atypical HUS and Crohn’s disease—interference of intestinal disease activity with complement-blocking treatment
por: Horváth, Orsolya, et al.
Publicado: (2021)

Risk of Atypical HUS Among Family Members of Patients Carrying Complement Regulatory Gene Abnormality
por: Ardissino, Gianluigi, et al.
Publicado: (2021)

Case Report: Atypical HUS Presenting With Acute Rhabdomyolysis Highlights the Need for Individualized Eculizumab Dosing
por: Benoit, Stefanie W., et al.
Publicado: (2022)

Haemolytic uraemic syndrome associated with non shiga toxin-producing Escherichia coli bacteraemia: a case report
por: Bally, Stéphane, et al.
Publicado: (2019)

Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome
por: Lemaire, Mathieu, et al.
Publicado: (2013)

Atypical hemolytic uremic syndrome (aHUS) responsive to mycophenolate mofetil: A case report from Nepal
por: Gurung, Jyoti, et al.
Publicado: (2022)

Case report: Short-term eculizumab use in atypical HUS associated with Lemierre's syndrome and post-infectious glomerulonephritis
por: Sadiq, Sanober, et al.
Publicado: (2023)

Ockham’s razor defeated: about two atypical cases of hemolytic uremic syndrome
por: Schwarz, Chloe, et al.
Publicado: (2020)

Co-Stimulatory Blockade of the CD28/CD80-86/CTLA-4 Balance in Transplantation: Impact on Memory T Cells?
por: Ville, Simon, et al.
Publicado: (2015)

Early relapse rate determines further relapse risk: results of a 5-year follow-up study on pediatric CFH-Ab HUS
por: Hofer, Johannes, et al.
Publicado: (2020)

Risk Factors for Short- and Long-Term Outcomes in Children With STEC-HUS/D(+) HUS: A Single-Center Experience
por: VanSickle, Judith Sebestyen, et al.
Publicado: (2018)

Letter regarding “Minimal change disease relapse following SARS-CoV-2 mRNA vaccine”
por: Schwotzer, Nora, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_5ig4qhqmtqm7igb2drf58argl2